ARHGEF17 Antibody

What is ARHGEF17 and what are its main functions in cellular processes?

• Interphase function: Acts as a RhoGEF regulating cytoskeleton organization through the Rho GTPase pathway

• Mitotic function: Serves as an essential spindle assembly checkpoint (SAC) factor by targeting the checkpoint kinase Mps1 to kinetochores, independently of its RhoGEF activity

The central domain of ARHGEF17 (aa 667-1,306) is sufficient for its SAC activity, while its GEF activity is mediated by the Dbl homology (DH) domain . ARHGEF17 is also highly expressed in blood vessels and has been implicated in intracranial aneurysm (IA) pathogenesis .

What are the standard applications for ARHGEF17 antibodies in research protocols?

ARHGEF17 antibodies are utilized in multiple experimental approaches:

For mitotic studies, immunofluorescence on chromosome spreads from nocodazole-arrested cells provides enhanced visualization of ARHGEF17 at kinetochores .

How should researchers select the appropriate ARHGEF17 antibody for their experiments?

Selection should be based on:

• Target epitope: Consider where the antibody binds - N-terminal, central domain, or C-terminal regions have different functional significance

• Validation status: Review validation data demonstrating specificity (e.g., RNAi knockdown controls)

• Applications: Confirm the antibody has been validated for your specific application

• Cross-reactivity: Be aware of potential cross-reactivity issues, especially with NuMA protein

• Species reactivity: Many antibodies react with human, mouse, and rat ARHGEF17

For studying ARHGEF17's mitotic function, select antibodies targeting the central domain (aa 667-1,306), which mediates Mps1 binding and kinetochore localization .

What controls should be included when using ARHGEF17 antibodies?

Essential controls include:

• Knockdown/knockout validation: siRNA depletion of ARHGEF17 (>80% reduction) should eliminate antibody signal

• Rescue experiments: Expression of siRNA-resistant constructs (e.g., mouse ARHGEF17 in human cells) can restore signal and confirm specificity

• Competing peptide control: Pre-incubation with immunizing peptide should abolish specific signal

• Cross-reactivity control: Test potential cross-reactivity with NuMA, especially for antibodies showing unexpected nuclear localization patterns

• Subcellular fractionation control: Compare cytoplasmic versus nuclear fractions to confirm expected distribution

How can researchers investigate ARHGEF17's role in the spindle assembly checkpoint?

Methodological approach:

• Protein depletion: Use siRNA targeting ARHGEF17 (validated with 4 independent siRNAs)

• Checkpoint assay: Treat cells with nocodazole and quantify mitotic index; ARHGEF17-depleted cells will fail to maintain checkpoint-dependent arrest

• Live-cell imaging: Monitor chromosome dynamics using H2B-mCherry to observe accelerated mitotic progression and polylobed nuclei formation

• Kinetochore protein localization: Perform ratiometric immunofluorescence to measure recruitment of SAC components (Mad2, BubR1, Bub1)

• Mps1 localization: Quantify Mps1 kinetochore localization, which is dependent on ARHGEF17

• Substrate phosphorylation: Assess phosphorylation of KNL1, an Mps1 substrate, using phospho-specific antibodies

Research has demonstrated that ARHGEF17 depletion phenocopies Mps1 inhibition rather than Aurora B inhibition, with cells showing accelerated mitotic timing (~12 minutes from nuclear envelope breakdown to anaphase versus ~32 minutes in controls) .

What are the known issues with ARHGEF17 antibodies and how can they be addressed?

Several challenges require careful consideration:

• NuMA cross-reactivity: Some commercial ARHGEF17/TEM4 antibodies cross-react with Nuclear Mitotic Apparatus protein 1 (NuMA)

  • Solution: Validate with GFP-tagged ARHGEF17 transfection in parallel with GFP-NuMA controls to identify cross-reactivity

• Cytoplasmic background: Endogenous ARHGEF17 detection can have high cytoplasmic background obscuring kinetochore signals

  • Solution: Use chromosome spreads from nocodazole-arrested cells for enhanced visualization

• Molecular weight variability: Reported molecular weights vary (222 kDa theoretical vs. 68 kDa observed by some antibodies)

  • Solution: Include positive controls with recombinant protein of known size

• Mitosis-specific interactions: ARHGEF17-Mps1 interaction is mitosis-specific

  • Solution: Ensure proper cell synchronization for interaction studies

How can ARHGEF17 antibodies be used to study intracranial aneurysm (IA) mechanisms?

ARHGEF17 has been identified as a risk gene for IA . Research approaches should include:

• Variant-specific investigations: Focus on the c.4394C>A_p.Ala1465Asp (rs2298808) variant associated with IA

  • Generate antibodies specific to this variant region or phosphorylation state

• Tissue expression studies: Perform IHC on vascular tissues with ARHGEF17 antibodies

  • ARHGEF17 is highly expressed in blood vessels compared to other tissues

• Zebrafish model analysis: Use ARHGEF17 antibodies in zebrafish studies

  • Arhgef17 knockdown causes blood extravasation in brain regions

  • Focus on endothelial lesions in cerebral blood vessels

• Mutation impact assessment: Compare wild-type versus mutant ARHGEF17 protein:

  • Localization differences

  • GEF activity alterations

  • Protein-protein interaction changes

The increased mutation burden for ARHGEF17 in IA cases versus controls (21/106 versus 11/306; P=8.1×10⁻⁷; OR=6.6) suggests this protein is a valuable target for understanding IA pathogenesis.

What are the phosphorylation sites on ARHGEF17 and how might they affect antibody recognition?

ARHGEF17 phosphorylation sites include:

• Mps1-dependent phosphorylation sites: Three threonine residues (T119, T312, and T375) were identified as Mps1 substrates by LC-MS/MS

• Phosphorylation state considerations:

  • Phosphorylation affects ARHGEF17-Mps1 interaction dynamics

  • Mps1 inhibition enhances ARHGEF17-Mps1 complex formation

  • Phospho-specific antibodies could detect active versus inactive states

When selecting antibodies, researchers should consider:

• Whether epitopes contain phosphorylation sites

• If phosphorylation state affects epitope accessibility

• Using phosphatase treatment as a control for phosphorylation-sensitive antibodies

Phospho-specific antibodies against ARHGEF17 could serve as biomarkers for SAC activity or IA risk assessment.

What methodologies are recommended for studying ARHGEF17-Mps1 interactions in mitotic cells?

Multiple complementary approaches should be used:

• Co-immunoprecipitation (Co-IP):

  • Synchronize cells in mitosis using nocodazole

  • Use anti-ARHGEF17 or anti-Mps1 antibodies for IP

  • Detect with reciprocal antibody in Western blot

  • Include Mps1 inhibitor (reversine) treatment to enhance complex formation

• Fluorescence Cross-Correlation Spectroscopy (FCCS):

  • Tag ARHGEF17 and Mps1 with spectrally distinct fluorophores

  • Measure protein-protein interactions in living cells

  • Compare interaction in interphase versus mitosis

  • Cross-correlation amplitude provides quantitative measure of binding

• In vitro binding assays:

  • Purify recombinant ARHGEF17 central domain and His-tagged Mps1

  • Perform pull-down assays with His-Mps1 protein bound to beads

  • Use unrelated proteins (e.g., His-BubR1 kinase domain) as negative controls

• Proximity ligation assay (PLA):

  • Detect endogenous protein interactions in fixed cells

  • Provides spatial information about interaction sites

These approaches revealed that the ARHGEF17-Mps1 interaction is mitosis-specific and regulated by Mps1 kinase activity .

How can researchers distinguish between ARHGEF17's interphase and mitotic functions in experimental designs?

To differentiate between ARHGEF17's dual functions:

• Domain-specific constructs:

  • Use truncated constructs containing only the central domain (aa 667-1,306) for mitotic function

  • Use GEF domain constructs for interphase cytoskeletal function

  • Test the Y1216A mutation that disrupts GEF activity without affecting mitotic function

• Cell synchronization:

  • Thymidine block/release for S-phase

  • Nocodazole treatment for prometaphase arrest

  • RO-3306 for G2 arrest

• Kinase inhibition approaches:

  • Reversine (Mps1 inhibitor) to disrupt mitotic function

  • Compare with Aurora B inhibition (hesperadin) to distinguish pathway involvement

• Spatiotemporal analysis:

  • Monitor chromosome dynamics with H2B-mCherry

  • Track mitotic progression timing (nuclear envelope breakdown to anaphase)

  • Quantify polylobed nuclei formation as indicator of mitotic errors

• Ratiometric immunofluorescence:

  • Systematically analyze localization of kinetochore proteins

  • Focus on outer kinetochore and checkpoint proteins (Mad2, BubR1, Bub1)

  • Compare with inner kinetochore and linker proteins

The mitotic function of ARHGEF17 is independent of its Rho GEF activity, allowing careful experimental design to separate these functions .